(VIANEWS) – Camtek Ltd. (CAMT), Materialise NV (MTLS), Progress Software Corporation (PRGS) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Camtek Ltd. (CAMT)
27.4% sales growth and 21.2% return on equity
Camtek Ltd., together with its subsidiaries, develops, manufactures, and sells inspection and metrology equipment for the advanced interconnect packaging, memory, complementary metal oxide semiconductor image sensors, micro-electro mechanical systems, radio frequency, and other segments of the semiconductor industry. It provides inspection and metrology systems, including Eagle-i, a system that delivers 2D inspection and metrology capabilities; Eagle-AP, which addresses the advanced packaging market using software and hardware technologies that deliver superior 2D and 3D inspection and metrology capabilities on the same platform; and Golden Eagle, a panel inspection and metrology system to support fanout wafer level packaging applications. The company sells its products in the Asia Pacific, the United States, and Europe. Camtek Ltd. was incorporated in 1987 and is headquartered in Migdal HaEmek, Israel.
Earnings Per Share
As for profitability, Camtek Ltd. has a trailing twelve months EPS of $1.97.
PE Ratio
Camtek Ltd. has a trailing twelve months price to earnings ratio of 39.35. Meaning, the purchaser of the share is investing $39.35 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.2%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 35.3% and 26.3%, respectively.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Apr 3, 2024, the estimated forward annual dividend rate is 1.33 and the estimated forward annual dividend yield is 1.72%.
2. Materialise NV (MTLS)
14.2% sales growth and 4.59% return on equity
Materialise NV provides additive manufacturing and medical software, and 3D printing services in the Americas, Europe and Africa, and the Asia-Pacific. It operates through three segments: Materialise Software, Materialise Medical, and Materialise Manufacturing. The Materialise Software segment offers software through programs and platforms that enable and enhance the functionality of 3D printers and of 3D printing operations. Its software interfaces between various types of 3D printers; and various software applications and capturing technologies, including computer-aided design/computer-aided manufacturing packages and 3D scanners. This segment serves 3D printing machine manufacturers; production companies and contract manufacturers in automotive, aerospace, consumer goods, and hearing aid industries; and 3D printing service bureaus through its sales force, Website, and third-party distributors. The Materialise Medical segment provides medical software that allows medical-image based analysis and engineering, as well as patient-specific design of surgical devices and implants. It serves medical device companies, hospitals, universities, research institutes, and industrial companies through its direct sales force, Website, and picture archiving and communication system partners. The Materialise Manufacturing segment provides 3D printing services, design and engineering services, and rapid prototyping and additive manufacturing of production parts to industrial and commercial customers. The company has collaboration agreements with Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc. Materialise NV was incorporated in 1990 and is headquartered in Leuven, Belgium.
Earnings Per Share
As for profitability, Materialise NV has a trailing twelve months EPS of $0.21.
PE Ratio
Materialise NV has a trailing twelve months price to earnings ratio of 24.52. Meaning, the purchaser of the share is investing $24.52 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.59%.
Yearly Top and Bottom Value
Materialise NV’s stock is valued at $5.15 at 16:22 EST, way below its 52-week high of $6.93 and higher than its 52-week low of $4.70.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 62.5% and positive 700% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 6.2%, now sitting on 257.86M for the twelve trailing months.
3. Progress Software Corporation (PRGS)
9.8% sales growth and 17.86% return on equity
Progress Software Corporation develops, deploys, and manages business applications. The company offers OpenEdge, a development software, which builds multi-language applications for secure deployment across various platforms and devices, as well as cloud; developer tools that consists of components for user interface development for Web, mobile, desktop, chat, and AR/VR apps, as well as automated application testing and reporting tools; Sitefinity, a web content management and customer analytics platform; Corticon, a business rules management system that provides applications with decision automation and change process, and decision-related insight capabilities. It also offers DataDirect Connect, which provides data connectivity using industry-standard interfaces to connect applications running on various platforms; MOVEit that offers secure collaboration and automated file transfers of critical business information; Chef, an infrastructure automation platform to build, deploy, manage, and secure applications in multi-cloud and hybrid environments, and on-premises; and WhatsUp Gold, a network monitoring solution. In addition, the company provides Kemp LoadMaster, a load balancing solutions; and Kemp Flowmon network performance monitoring and diagnostic solutions that collect and analyze network telemetry from various sources. Further, it provides project management, implementation, custom development, programming, and other services, as well as web-enable applications; and training services. The company sells its products to end users, independent software vendors, original equipment manufacturers, and system integrators. It has operations in the United States, Canada, Latin America, Europe, the Middle East, Africa, and the Asia Pacific. The company was founded in 1981 and is headquartered in Burlington, Massachusetts.
Earnings Per Share
As for profitability, Progress Software Corporation has a trailing twelve months EPS of $1.63.
PE Ratio
Progress Software Corporation has a trailing twelve months price to earnings ratio of 35.33. Meaning, the purchaser of the share is investing $35.33 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.86%.
4. Kamada Ltd. (KMDA)
9.5% sales growth and 7.05% return on equity
Kamada Ltd., together with its subsidiaries, provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. It has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. Kamada Ltd. was incorporated in 1990 and is headquartered in Rehovot, Israel.
Earnings Per Share
As for profitability, Kamada Ltd. has a trailing twelve months EPS of $0.27.
PE Ratio
Kamada Ltd. has a trailing twelve months price to earnings ratio of 20.19. Meaning, the purchaser of the share is investing $20.19 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.05%.
Sales Growth
Kamada Ltd.’s sales growth is 7.9% for the ongoing quarter and 9.5% for the next.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is 16.7% and a drop 33.3% for the next.
Yearly Top and Bottom Value
Kamada Ltd.’s stock is valued at $5.45 at 16:22 EST, way under its 52-week high of $6.53 and way above its 52-week low of $4.08.
Moving Average
Kamada Ltd.’s value is below its 50-day moving average of $5.61 and under its 200-day moving average of $5.60.
